Tumor News and Research

RSS

Study sheds light on why lung tumors do not respond well to immunotherapy

Immunotherapy -; drug treatment that stimulates the immune system to attack tumors -; works well against some types of cancer, but it has shown mixed success against lung cancer.

6 Feb 2023

Employing molecular anchor for more effective CAR immunotherapies

Researchers at St. Jude Children’s Research Hospital discovered that immune cells with the attached protein boosted the killing of cancer, irrespective of the kind of cancer cell or the type of cancer being targeted.

3 Feb 2023

Losartan prevents immunotherapy-related edema, improves survival in glioblastoma mouse models

Patients with glioblastoma-;the deadliest type of primary brain tumor-;may potentially benefit from immunotherapy medications called immune checkpoint inhibitors that stimulate an immune response against cancer cells.

3 Feb 2023

Cancer therapies improved by changing an antibody’s binding to a target

Before World Cancer Day (4th February), new research from the Centre for Cancer Immunology at the University of Southampton has demonstrated that altering how firmly an antibody attaches to a target can enhance cancer treatments.

2 Feb 2023

Scientists define four cancer molecular subtypes using PDX models

Metastasis, the process by which cancer cells leave the primary tumor and spread to other tissues to seed new cancerous growth, causes most cancer deaths.

2 Feb 2023

Scientists develop new design principles to improve cancer vaccines

A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.

1 Feb 2023

Molecular staple: The DNA repair mechanism impeding cancer treatment

Due to the continuous cellular activity, malfunctions frequently occur, making error-correcting systems crucial for cells. However, it serves the cancer cells’ best interests to cause errors when it comes to destroying them.

30 Jan 2023

Novel protein degradation technology provides functional insights into how CTCF regulates transcription

CTCF is a critical protein known to play various roles in key biological processes such as transcription.

30 Jan 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Analysis of pancreatic cancer's microenvironment reveals cause of tumor cell resistance to immunotherapy

A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.

27 Jan 2023

Persistent tumor mutation load may help predict outcome of novel immunotherapies

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.

27 Jan 2023

Tumor progression after immunotherapy: Molecular pathways revealed

The University of Michigan’s Rogel Cancer Center researchers discovered a mechanism that explains why a subset of patients’ tumors grows rather than shrink when treated with immunotherapy.

20 Jan 2023

Innovative approach to mRNA delivery

A group of scientists spearheaded by The University of Texas MD Anderson Cancer Center has created a unique messenger RNA (mRNA) delivery system utilizing extracellular vesicles (EVs).

16 Jan 2023

New gene helps drive the development of the common lung cancer type

At the NYU Langone Health’s Perlmutter Cancer Center, a team headed by scientists has determined a gene that forces the development of the second most common type of lung carcinoma.

From New York University (NYU) 11 Jan 2023

Improving cancer immunotherapies with bioengineered synthetic gene circuits

In two distinct studies, scientists show how synthetic biology can be used to address a challenging problem in cancer immunotherapy: the way immunotherapy-related approaches focused on the short-term killing of tumor cells could fail to eradicate tumors because tumor growth occurs on longer timescales.

19 Dec 2022

Predictive classifier identifies patients who can skip radiation therapy

According to the findings of a meta-analysis proposed at the San Antonio Breast Cancer Symposium held on December 6–10th, 2022, patients with invasive breast cancer who had low scores on an investigational gene molecular signature seemed to have similar rates of local recurrence regardless of whether they received adjuvant radiation therapy after breast-conserving surgery.

12 Dec 2022

New 3D organoid model reveals a possible biological target for treating GEJ cancers

Researchers at Johns Hopkins Medicine say they have created a laboratory-grown three-dimensional "organoid" model that is derived from human tissue and designed to advance understanding about how early stages of cancer develop at the gastroesophageal junction (GEJ) — the point where the digestive system's food tube meets the stomach.

2 Dec 2022

Revealing the unappreciated role of POLQ in responding to DNA replication stress

Researchers at the Francis Crick Institute, in partnership with Artios, have discovered how an enzyme involved in DNA repair (POLQ) becomes critical to the survival of some tumors when the cancer cells lose the ability to employ a more frequent way of DNA repair.

1 Dec 2022

Breakthrough on the way to new therapeutic strategies

As far as the field of cancer research is concerned, hollow spheres composed of MYC proteins sets the stage. Researchers from Würzburg have found them out and have reported this discovery in the Nature journal.

25 Nov 2022

Revealing cancer development in people carrying inherited BRCA1 mutations

Researchers from Weill Cornell Medicine have discovered that people who inherit a mutant copy of the BRCA1 gene may develop mutations and cancer due to error-prone DNA replication and repair.

16 Nov 2022

Tumor News and Research

Study sheds light on why lung tumors do not respond well to immunotherapy

Employing molecular anchor for more effective CAR immunotherapies

Losartan prevents immunotherapy-related edema, improves survival in glioblastoma mouse models

Cancer therapies improved by changing an antibody’s binding to a target

Scientists define four cancer molecular subtypes using PDX models

Scientists develop new design principles to improve cancer vaccines

Molecular staple: The DNA repair mechanism impeding cancer treatment

Novel protein degradation technology provides functional insights into how CTCF regulates transcription

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Analysis of pancreatic cancer's microenvironment reveals cause of tumor cell resistance to immunotherapy

Persistent tumor mutation load may help predict outcome of novel immunotherapies

Tumor progression after immunotherapy: Molecular pathways revealed

Innovative approach to mRNA delivery

New gene helps drive the development of the common lung cancer type

Improving cancer immunotherapies with bioengineered synthetic gene circuits

Predictive classifier identifies patients who can skip radiation therapy

New 3D organoid model reveals a possible biological target for treating GEJ cancers

Revealing the unappreciated role of POLQ in responding to DNA replication stress

Breakthrough on the way to new therapeutic strategies

Revealing cancer development in people carrying inherited BRCA1 mutations

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics